Business
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026Well-positioned to deliver on key milestones with approximately
About this update from Cg Oncology, Inc.
[{"type":"image","alt":"CG Oncology Inc.","displaySize":"","headline":null,"caption":"CG Oncology Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/e6d84dc2dcd899e87f2706074c7ed4f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yn9PcvAQZE97v9_BbPMqQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/e6d84dc2dcd899e87f2706074c7ed4f8","width":300,"height":51},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/yn9PcvAQZE97v9_BbPMqQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcx/https://media.zenfs.com/en/globenewswire.com/e6d84dc2dcd899e87f2706074c7ed4f8","width":300,"height":51}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 ","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Well-positioned to deliver on key milestones with approximately $1.1 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029","length":168,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":604,"olType":false},{"type":"text","content":"DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.","length":186,"tagName":"p"},{"type":"text","content":"“We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and we are on track to finalize our submission in the fourth quarter 2026. We are pleased to provide this additional guidance on expected BLA completion following focused filing discussions with FDA. Manufacturing inspection readiness activities continue to progress, including our commi...